En DE FR ES PL
HUMOG - instructions for use, testimonials, analogues and forms of release (injections in ampoules for injection 75 IU + 75 IU and 150 IU + 150 IU lyophilizate) drugs for infertility treatment in women and men and for controlled superovulation with IVF. Composition

HUMOG - instructions for use, testimonials, analogues and forms of release (injections in ampoules for injection 75 IU + 75 IU and 150 IU + 150 IU lyophilizate) drugs for infertility treatment in women and men and for controlled superovulation with IVF. Composition

In this article, you can read the instructions for using the drug Humog. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Humog in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Humog in the presence of existing structural analogues. Use for the treatment of male and female infertility and for controlled superovulation with IVF. Composition of the preparation.

 

Humog - human menopausal gonadotropin.Increases the level of sex hormones in the blood plasma. In women, it stimulates the maturation of follicles in the ovaries (before the pre-ovarian stage), increases the level of estrogens, activates the proliferation of the endometrium. In men, it affects the Sertoli cells of the seminiferous tubules and induces spermatogenesis. Strengthens the production of steroid hormones by the sex glands. Effectiveness is mainly due to the action of follicle-stimulating hormone.

 

Composition

 

Follicle-stimulating hormone + Luteinizing hormone + Sodium chloride 0,9% (solvent) + auxiliary substances.

 

Pharmacokinetics

 

The maximum concentration of follicle-stimulating hormone is reached 6-24 hours after intramuscular injection. The half-life period is 4-12 hours. It is excreted mainly by the kidneys.

 

Indications

  • female infertility associated with a violation of the process of maturation of follicles, in particular against the background of a deficiency of the yellow body of the ovaries;
  • stimulation of superovulation (growth of multiple follicles) for assistive reproductive techniques (IVF) that promote pregnancy, in combination with human chorionic gonadotropin;
  • male infertility associated with a violation of spermatogenesis on the background of hypogonadism of the hypothalamic-pituitary genesis;
  • azoospermia, oligoastenospermia in men (absence or insufficient for fertilization of the number of mobile spermatozoa in the ejaculate).

 

Forms of release

 

Lyophilizate for the preparation of a solution for intramuscular administration of 75 IU + 75 IU and 150 IU + 150 IU with a solvent (injections in ampoules for injection).

 

Instructions for use and dosing regimen

 

Humog is injected intramuscularly or subcutaneously, the solution is prepared immediately before injection using the supplied solvent. In 1 ml of solvent can dissolve the contents of 5 ampoules. To stimulate the growth of one dominant follicle among women two different injection schemes are used.


The first scheme: daily administration in a dose of 75 IU in the first 7 days of the cycle in menstruating women. Injections continue until an adequate response is reached, judged on the onset of which is possible by daily analyzes of the concentration of estrogens and determination of the size of the follicles by ultrasound. Maturation of follicles occurs usually during the treatment cycle lasting 7-12 days.In the absence of ovarian response to administration, the daily dose of the drug can be gradually increased to 150 IU.


The second scheme: an introduction every other day for 1 week. The initial dose is 225-375 IU per day. If adequate stimulation is not achieved, the dose may be gradually increased.


After carrying out treatment for any of the schemes and in the presence of adequate but not excessive ovarian response, determined from clinical and biochemical studies, 24-48 hours after the last administration of Humog, for the induction of ovulation, 5-10 thousand IU of human chorionic gonadotropin , increasing the content of luteinizing hormone and stimulating the release of a mature egg.


In the presence of ovulation and the absence of pregnancy, treatment can be repeated according to one of the above schemes for 2 cycles. On the day of the introduction of chorionic gonadotropin and the next 2-3 days, the patient is recommended to have sexual intercourse. When stimulating superovulation with assisted reproductive techniques, the duration of drug administration may be longer.


Application in men

 

When hypogonadotropic hypogonadism in men for stimulation of spermatogenesis, the drug is prescribed if the previous therapy with human chorionic gonadotropin caused only an androgenic reaction without signs of increased spermatogenesis. In this case, the treatment is continued by administering 2 thousand IU of human chorionic gonadotropin 2 times a week, along with Humogog injections of 75 IU 3 times a week. Treatment for this scheme should be continued at least for 4 months, if ineffectiveness treatment is continued, introducing human chorionic gonadotropin 2,000 IU twice a week, and 150 IU of Khumoga 3 times a week.


The state of spermatogenesis should be assessed on a monthly basis, and if there are no positive results within the next 3 months, treatment should be discontinued. With idiopathic normogonadotrophic oligospermia, 5,000 IU of human chorionic gonadotropin are administered weekly, either subcutaneously or intramuscularly, with parallel administration of 75-150 IU of Humohoma 3 times a week, for 3 months.


For the purpose of stimulation of spermatogenesis, 1-3,000 IU of chorionic gonadotropin 3 times a week before the normalization of testosterone concentration in the blood.After that, for several months 3 times a week - 75-150 IU of Humog.

 

Side effect

  • mastalgia (tenderness of the mammary glands);
  • gynecomastia (increased mammary glands in men);
  • ovarian hyperstimulation syndrome (oliguria, edema, nausea, vomiting, fever, lower abdominal pain, low blood pressure);
  • ovarian enlargement and cyst formation;
  • hypovolemia (decrease in the volume of circulating blood);
  • ascites (accumulation of fluid in the abdominal cavity);
  • electrolyte imbalance;
  • hydrothorax (accumulation of fluid in the pleural cavity);
  • urticaria (a rash of allergic origin);
  • arthralgia (joint pain);
  • pain in the injection site;
  • thromboembolism (clotting of a vessel by a thrombus);
  • multiple pregnancy.

 

Contraindications

  • uterine myoma;
  • estrogen-dependent tumors of the ovaries, uterus, breast;
  • prostate cancer, testes and other androgen-dependent tumors in men;
  • tumors of the hypothalamus and pituitary gland;
  • hyperprolactinemia (increased prolactin levels in the blood);
  • gynecological bleeding of unclear etiology;
  • hypertrophy and ovarian cysts;
  • primary failure of the ovaries;
  • hypersensitivity to the components of the drug;
  • diseases of the kidneys, adrenals, pancreas and thyroid gland;
  • abnormalities of genitalia incompatible with the normal course of pregnancy;
  • pregnancy and lactation;
  • childhood.

 

With care, Humog should be used in the presence of risk factors for thromboembolism:

  • individual or family predisposition;
  • severe obesity;
  • thrombophilia.

 

Application in pregnancy and lactation

 

Hemog contraindicated during pregnancy and lactation.

 

Use in children

 

The drug is not used in pediatric practice.

 

special instructions

 

Before starting treatment, women need a gynecological examination, exclude ovarian exhaustion or resistance syndrome, and analyze the semen of the sexual partner. During the period of therapy, daily hormonal control and ultrasound of the developing follicles are mandatory (the reaction of the ovaries can be evaluated according to the cervical index).

 

Before the appointment of the drug, it is necessary to conduct appropriate treatment for violations of the thyroid gland or adrenal cortex, hyperprolactinaemia of various etiologies, tumors of the hypothalamic-pituitary region.Before the beginning of treatment it is necessary to exclude extragenital endocrinopathies.

 

In women with infertility, in relation to which auxiliary reproductive technologies are used, there are often anomalies of the fallopian tubes, which increases the risk of ectopic pregnancy localization. Therefore, it is important to obtain an early ultrasound confirmation of the location of the fetal egg in the uterine cavity. It should be borne in mind that as a result of treatment there may be a multiple pregnancy.

 

If signs of ovarian hyperstimulation occur, treatment should be discontinued.

 

In men with a high level of follicle-stimulating hormone in the blood, menotropins are ineffective.

 

The prepared drug solution is used immediately.

 

Impact on the ability to drive vehicles and manage mechanisms

 

There are no reports on the effect of the drug on the ability to drive vehicles and mechanisms.

 

Drug Interactions

 

In women with symptoms of excessive ovarian stimulation caused by the use of menotropins, the administration of drugs with luteinizing hormone activity increases the risk of developing the ovarian hyperstimulation syndrome.

 

The effect is weakened by gonadotropin-releasing hormone agonists. Clomiphene increases the reaction of the follicle.

 

The drug should not be administered in the same injection with other drugs.

 

Studies have shown that the co-administration of menotropin and urofollitropin does not significantly change the bioactivity that is expected.

 

Analogues of medicinal product Humog

 

Structural analogs for the active substance:

  • Gonadotropin is menopausal;
  • Menogon;
  • Menopur;
  • Menopur Multidose;
  • The Merial;
  • Pergonal;
  • Houmegon.

 

Analogues on the pharmacological group (hormones of the pituitary, hypothalamus, gonadotropins and their antagonists):

  • Atosiban;
  • Buserelin;
  • Genirelix;
  • Goserelin;
  • Gonadotropin is chorionic;
  • Danazol;
  • Carbetocin;
  • Coriphyltroline alpha;
  • Lutropin alfa;
  • Sigetin;
  • Triptorelin;
  • Urofoltotropin;
  • Foliotropin alfa;
  • Foliotropin beta;
  • Hinagolide;
  • Choriogonadotropin alfa;
  • Cetrorelix.

 

Response of a reproductive health specialist

 

Humog - a good Indian drug for stimulating ovulation, increasing the number of follicles. It is used both to increase the chances of a natural pregnancy, and when planning IVF.Humor does not suit everyone, some patients do not respond, while others have a high sensitivity (from 20 to 40 eggs in the first cycle). Although the drug is considered obsolete, it is affordable and no less effective than the more expensive counterparts Menopur, Menogon. The main disadvantage - it is undesirable to use it in the syndrome of polycystic ovaries, in this case Klostilbegit is appointed.

 

 

Similar medicines:

Other medicines:

Reviews (0):

Rules for publishing reviews and visitor questions